Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 9679

BillFederalHouseIn Committee
To increase the number of manufacturers registered under the Controlled Substances Act to manufacture cannabis for legitimate research purposes, to authorize health care providers of the Department of Veterans Affairs to provide recommendations to veterans regarding participation in federally approved cannabis clinical trials, and for other purposes.
About This Bill
Committee
Latest Action · December 22, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress
117th (2021–2023)
Introduced
December 22, 2022
Cosponsors (0)
None
View PDF ↗

Summary

Highlight any text to annotate
Medical Cannabis Research Act of 2022 This bill establishes a new, separate registration process for manufacturers of cannabis for research. As a part of this process, the Drug Enforcement Administration must annually assess whether there is an adequate and uninterrupted supply of research cannabis and register additional manufacturers. The bill also authorizes health care providers of the Department of Veterans Affairs to provide information to veterans regarding participation in federally approved cannabis clinical trials.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.